The Potential Role of Polymerase Chain Reaction in Diagnosis of Neonatal Herpes Simplex Virus Infection: Is Viral Culture Outdated?
Even in the era of effective antiviral therapy, neonatal herpes simplex viral infection causes significant morbidity and mortality in newborns. Prompt diagnosis is the cornerstone of treatment of these infants. Outside and inside the neonatal clinical practice, polymerase chain reaction (PCR) is replacing culture as a method of facilitating a speedy diagnosis of herpes simplex virus infection. New pediatric guidelines call for testing of high-risk asymptomatic infants, and thus, many more surface cultures and PCRs are being performed. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - June 6, 2017 Category: Microbiology Authors: Nicole L. Samies, Swathi M. Gowtham Source Type: news
IRE1{alpha} promotes viral infection by conferring resistance to apoptosis
The unfolded protein response (UPR) is an ancient cellular pathway that detects and alleviates protein-folding stresses. The UPR components X-box binding protein 1 (XBP1) and inositol-requiring enzyme 1α (IRE1α) promote type I interferon (IFN) responses. We found that Xbp1-deficient mouse embryonic fibroblasts and macrophages had impaired antiviral resistance. However, this was not because of a defect in type I IFN responses but rather an inability of Xbp1-deficient cells to undergo viral-induced apoptosis. The ability to undergo apoptosis limited infection in wild-type cells. Xbp1-deficient cells were generall...
Source: Signal Transduction Knowledge Environment - June 6, 2017 Category: Science Authors: Fink, S. L., Jayewickreme, T. R., Molony, R. D., Iwawaki, T., Landis, C. S., Lindenbach, B. D., Iwasaki, A. Tags: STKE Research Articles Source Type: news
Risk of HBV Reactivation in Patients on Antivirals for HCV Risk of HBV Reactivation in Patients on Antivirals for HCV
Is there a clinically relevant risk of HBV reactivation during direct-acting antiviral therapy for HCV with an interferon-free regimen?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
HBIG Plus Antivirals May Prevent HBV Reinfection After Transplant HBIG Plus Antivirals May Prevent HBV Reinfection After Transplant
A very short course of hepatitis B immunoglobulin (HBIG) after liver transplantation, along with long-term antiviral therapy, may prevent hepatitis B virus (HBV) reinfection, a retrospective study suggests.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 22, 2017 Category: Transplant Surgery Tags: Transplantation News Source Type: news
Prevalence and Impact of Steatohepatitis in HBV Patients Prevalence and Impact of Steatohepatitis in HBV Patients
This study assessed the prevalence of steatohepatitis in chronic HBV-infected patients, its risk factors, and its correlation with liver fibrosis and response to antiviral therapy.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Dateline City:
KENILWORTH, N.J. Findings Presented at The International Liver Congress ™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the first sustained virologic response1 (SVR)
results 12 weeks after completion of therapy (SVR12, considered
virologic cure) fromC-SURGE,
an ongoing, open label Phase 2 clinical trial evaluating MK-3682B
[uprifosbuvir (MK-3682)2/...
Source: Merck.com - Research and Development News - April 22, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hepatitis C MSD NYSE:MRK Source Type: news
Hepatitis C treatment can be provided successfully at syringe programme sites
Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City. (Source: PHPartners.org)
Source: PHPartners.org - April 19, 2017 Category: Global & Universal Source Type: news
Poor Adherence to Antiviral Treatment for Hepatitis B Poor Adherence to Antiviral Treatment for Hepatitis B
Antiviral therapy for hepatitis B is effective and improves outcomes, but is often long-term, and adherence can be poor. What factors might influence non-adherence to therapy?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 9, 2017 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news
Scientists crack the structure of HIV machinery
Antiviral therapy could be improved with newly uncovered atomic-level details of the structure of HIV machinery, report researchers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 5, 2017 Category: Science Source Type: news
Salk scientists crack the structure of HIV machinery
(Salk Institute) Antiviral therapy could be improved with the newly uncovered atomic-level details. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 5, 2017 Category: Biology Source Type: news
Novel Treatment Could Lead to Functional Control of Hep B Novel Treatment Could Lead to Functional Control of Hep B
Nucleic acid polymers block the release of the hepatitis B surface antigen from hepatocytes, boosting the efficacy of standard antiviral therapy, according to an early clinical trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 17, 2016 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Costs of HCV greater without antiviral therapy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 31, 2016 Category: Drugs & Pharmacology Source Type: news
Comparative Effectiveness of HCV Combination Therapies Comparative Effectiveness of HCV Combination Therapies
This analysis compared the efficacy of two commonly used regimens of oral antiviral therapy in a cohort of veterans with hepatitis C.Alimentary Pharmacology & Therapeutics (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 9, 2016 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news
Big step towards cure for HIV and other lifelong viral infections
New research has taken us a step closer to finding a cure for human immunodeficiency virus (HIV), as well as other infections including the glandular fever virus, which is associated with the development of lymphoma. Some infections, such as HIV, cannot be cured with antiviral therapy because the virus effectively hides from the immune system. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 4, 2016 Category: Science Source Type: news
Big step towards cure for lifelong viral infections
(Monash University) New research has taken us a step closer to finding a cure for human immunodeficiency virus (HIV), as well as other infections including the glandular fever virus, which is associated with the development of lymphoma. Some infections, such as HIV, cannot be cured with antiviral therapy because the virus effectively hides from the immune system. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 3, 2016 Category: Global & Universal Source Type: news
